Ibrutinib
The pill that ended chemotherapy for most CLL. It blocks the survival signal B cells depend on, and it was the first drug to beat chemoimmunotherapy in nearly every CLL setting.
Approved 2014 (relapsed CLL, RESONATE), 2016 (frontline, RESONATE-2), and with venetoclax as fixed-duration therapy (GLOW, CAPTIVATE; EU 2022). Also mantle cell lymphoma (withdrawn in the US 2023), Waldenström, marginal zone (withdrawn), and chronic GVHD. Off-target inhibition of EGFR, TEC, and CSK causes atrial fibrillation (~10-16%), hypertension, bleeding, and arthralgia; head-to-head trials (ELEVATE-RR, ALPINE) showed acalabrutinib and zanubrutinib are better tolerated, and zanubrutinib more effective, so ibrutinib is now second choice where alternatives exist.
1.B-cell receptor engagement activates BTK in the CLL cell
- Route
- Oral
- Schedule
- 420 mg once daily continuously until progression (CLL); 560 mg in MCL
- Monitoring
- Atrial fibrillation, hypertension, bleeding (hold around surgery), infections, cytopenias
Source: US prescribing information (DailyMed). Doses are for orientation; the current label governs.
- Medicare
- Part D (self-administered)
Oral, self-administered, so it is a Part D drug: covered through a stand-alone Part D plan or Medicare Advantage drug benefit, usually on the specialty tier with 25 to 33% coinsurance until the annual cap ($2,000 in 2025, $2,100 in 2026). Imbruvica was in the first group of ten drugs negotiated under the Inflation Reduction Act: the Medicare maximum fair price of $9,319 per 30-day supply took effect 1 January 2026, a 38% cut from the 2023 list price.
- Commercial insurance
- covered with prior authorisation
Covered for FDA-labelled and NCCN-listed uses, but almost always behind prior authorisation confirming diagnosis, biomarker and line of therapy; dispensed through a specialty pharmacy. Several PBMs now prefer acalabrutinib or zanubrutinib over ibrutinib for CLL on the basis of head-to-head trials.
- List price
- $14,934 per 30-day supply, 2023 list price; negotiated Medicare price $9,319 from 2026
CMS fact sheet, Medicare Drug Price Negotiation Program negotiated prices for 2026 (2023). Net prices after rebates are usually lower.
- Assistance programmes
- Johnson & Johnson withMe
- Johnson & Johnson Patient Assistance Foundation
- myAbbVie Assist
- PAN Foundation — Disease-specific co-pay and premium funds; open and closed funds change monthly.
- HealthWell Foundation
- CancerCare Co-Payment Assistance Foundation
- Patient Advocate Foundation Co-Pay Relief
- Leukemia & Lymphoma Society financial support
Part D out-of-pocket capped at $2,000 (2025) / $2,100 (2026). Medicare patients cannot use manufacturer co-pay cards; charity funds (PAN, HealthWell, CancerCare) and the Extra Help subsidy are the routes.
Sources: Medicare.gov: Drug coverage (Part D) · Medicare.gov: Costs for Medicare drug coverage (annual out-of-pocket cap) · CMS: Medicare Drug Price Negotiation Program · CMS fact sheet: negotiated prices for 2026 (August 2024). Not medical or financial advice; verify with your plan.
- Appraised for
- CLL after 1 prior therapy, or untreated CLL with 17p deletion or TP53 mutation
- Notes
- Waldenström macroglobulinaemia: TA491 (2017). Relapsed or refractory mantle cell lymphoma: TA502 (2018). Untreated CLL without high-risk features recommended 2021.
- NHS England
- Routinely funded for the appraised indication (or via managed access)
Sources: NICE TA429 · SMC advice: ibrutinib. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
- 13 Nov 2013ApprovalUS
Mantle cell lymphoma (accelerated); first BTK inhibitor
- 12 Feb 2014ApprovalUS
Relapsed CLL
- 4 Mar 2016ApprovalUS
First-line CLL
- 6 Apr 2023WithdrawalUS
MCL and MZL indications voluntarily withdrawn after confirmatory trials missed
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 2014 | Relapsed CLL (RESONATE); del(17p) CLL |
| US | 2016 | First-line CLL (RESONATE-2) |
| EU | 2022 | Fixed-duration ibrutinib + venetoclax, first-line CLL (GLOW, CAPTIVATE) |
| Adverse event | Any grade | Grade 3+ |
|---|---|---|
| Atrial fibrillation Pooled long-term CLL data; 5% grade ≥3 | 16% | — |
| Hypertension Cumulative over years | 42% | — |
| Major haemorrhage | 4% | — |
| Diarrhoea | 50% | — |
| Arthralgia | 30% | — |
Rates read from the US prescribing information. Blank cells mean the figure was not sourced, not that it is zero.
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials in OnCo
ELEVATE-TN put a more selective BTK inhibitor into first-line CLL and, with the head-to-head ELEVATE-RR trial, showed it is as effective as ibrutinib with fewer cardiac side effects. Continuous acalabrutinib became one of the two main front-line options alongside fixed-duration venetoclax combinations. The trade-off is indefinite therapy and cost versus a time-limited course.
ZUMA-2 gave patients with BTK-inhibitor-refractory mantle cell lymphoma, who previously had a median survival under a year, a therapy with durable remissions in a substantial fraction. Brexu-cel is now standard after BTK inhibitor failure and CAR-T is being tested earlier in the disease. Neurotoxicity rates are higher than in other lymphoma CAR-T trials.
Latest papers
topQuery for this drug: (TITLE:"Ibrutinib" OR ABSTRACT:"Ibrutinib" OR TITLE:"Imbruvica" OR ABSTRACT:"Imbruvica") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Ibrutinib, not a curated reading list.